Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  Akt inhibitor MK2206
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Erlotinib Hydrochloride, Akt Inhibitor MK2206, Selumetinib, or Sorafenib Tosylate in Treating Patients with Previously Treated Stage III-IV Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-0360, NCI-2011-01104, NCT01248247
Targeted Enzyme Inhibitor Therapy in Treating Patients with Advanced Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Thymic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0096, NCI-2013-01478, 110096, P10782, P8639_A15PAMDREVW01, 8639, NCT01306045
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ET-2011-041, NCI-2012-00081, 2011-001970-25, CDR0000716384, LEONB-ET-2011-041, 9022, NCT01481129
Akt Inhibitor MK-2206 and Anastrozole with or without Goserelin Acetate in Treating Patients with Stage II-III Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1139, NCI-2013-00080, 9170, NCT01776008
Akt Inhibitor MK2206 in Treating Patients with Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0431, NCI-2013-00487, 9340, NCT01802320
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients with Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 051105, NCI-2012-00084, CDR0000717546, CINJ-051105, 8983, NCT01480154
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients with Pancreatic Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1269, NCI-2013-00153, NA_00075037, 9231, NCT01783171
Start Over